Hypericin lights up the way for the potential treatment of nasopharyngeal cancer by photodynamic therapy

Curr Clin Pharmacol. 2006 Sep;1(3):217-22. doi: 10.2174/157488406778249370.

Abstract

Photodynamic therapy (PDT) involves the administration of a photosensitizer followed by light irradiation with a specific wavelength, giving rise to irreversible tissue destruction. Hypericin, a herbal extract derived from Hypericum perforatum or St. John's Wort, has minimal toxicity but exhibits potent photo-damaging effects in the presence of light. Hypericin is known to generate a high yield of singlet oxygen and other reactive oxygen species that are associated with photo-oxidative cellular damage. The application of PDT with hypericin for the treatment of cancers such as recurrent mesothelioma and skin cancer has been validated in clinical trials. This mini-review focuses on the investigative studies of hypericin as a potential photodynamic agent in the treatment of nasopharyngeal cancer (NPC) in in vitro and in vivo models. NPC is an enigmatic tumor with a multifactorial etiology and a high incidence in the populations of Southern China.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anthracenes
  • Cytokines / biosynthesis
  • Humans
  • Lipid Peroxidation / drug effects
  • Matrix Metalloproteinase 1 / genetics
  • Nasopharyngeal Neoplasms / drug therapy*
  • Nasopharyngeal Neoplasms / metabolism
  • Perylene / analogs & derivatives*
  • Perylene / pharmacokinetics
  • Perylene / therapeutic use
  • Photochemotherapy / methods*
  • Reactive Oxygen Species

Substances

  • Anthracenes
  • Cytokines
  • Reactive Oxygen Species
  • Perylene
  • hypericin
  • Matrix Metalloproteinase 1